Acne VulgarisNCT07062081
Correlation Between Acne Vulgaris and Lipid Profile Among Young Adults in Sohag Governorate
A study testing lipid profile in people with Acne Vulgaris, run by Sohag University at 1 site in Egypt.
Trial summary
Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from… Read more about this study
- Who is it for?
- Ages 12 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Acne Vulgaris
- What is being tested?
- lipid profile
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2025to 30 Jan 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 45 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- age- and sex-matched healthy volunteers, not taking any medicine, and having no personal or family history of acne.
Who cannot join
- : reluctance to take part in the study, pregnancy or lactation
- intake of oral contraception or hormone therapy, history of taking any medications that affect lipid metabolism or oral isotretinoin
- and systemic diseases that affect the metabolism of lipids, such as uncontrolled diabetes, hypothyroidism, nephrotic syndrome, end-stage renal failure, HIV, familial hypercholesterolemia, and metabolic syndrome.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
hanan A metwaly, professor contact
About this study
Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11
Read the detailed description
Acne vulgaris is a multifactorial disorder of the pilosebaceous unit, resulting from sebum overproduction, follicular hyperkeratinization, inflammation, and bacterial colonization of hair follicles by Propionibacterium acnes. The sebaceous gland is controlled primarily by hormonal stimulation. In this way, the hormonal effect on sebum secretion is a key to the pathogenesis of acne.12-16 During puberty, alteration of the sebum component, called dysseborrhea, stress, irritation, cosmetics, and potential dietary factors lead to the formation of acne lesions.16 Changes in sebum secretion are considered to be an important factor of acne. In this way, increased sebum secretion can induce acne occurrence.17 Increasing evidence, in essence, indicates that changes in lipid profile are strongly related to acne occurrence. Accordingly, further information and awareness campaigns are needed to emphasize the role of balanced lipid metabolism to control acne. Although a correlation between the incidence of acne and lipid profile levels has been observed before, it must be documented in each population with etiological characteristics. Minimal reports are available on the relationship between plasma lipids and acne in our country. Hence, we aim to establish this study to estimate the presence of lipid alteration in acne patients.
- Conditions
- Acne Vulgaris
- Being tested
- lipid profile
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
lipid profileDiagnostic test
The blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values.
What is being measured
The primary outcome is the main question the study is designed to answer.
lipid profile (TG)
The blood samples were taken to measure lipid profile levels as triglycerides (TG)
Measured: 6 months
lipid profile (HDL)
The blood samples were taken to measure lipid profile levels as HDL
Measured: 6 months
lipid profile (VLDL)
The blood samples were taken to measure lipid profile levels as VLDL
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start1 Aug 2025 (estimated)
- Primary completion30 Jan 2026 (estimated)
- Study completion30 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Acne VulgarisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hager Ali Dardier, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07062081
- Sponsor's protocol ID
- Soh-Med-25-06-18MS
- Status last verified
- Jul 2025
- First submitted
- 2 Jul 2025
- Last updated
- 14 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Degitz K, Ochsendorf F. Pharmacotherapy of acne. Expert Opin Pharmacother. 2008 Apr;9(6):955-71. doi: 10.1517/14656566.9.6.955.
PubMed 18377339Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996 Sep;35(9):633-9. doi: 10.1111/j.1365-4362.1996.tb03687.x.
PubMed 8876289Dreno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 5:14-9. doi: 10.1111/jdv.13188.
PubMed 26059821Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan;58(1):56-9. doi: 10.1016/j.jaad.2007.06.045. Epub 2007 Oct 22.
PubMed 17945383
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Between Acne Vulgaris and Lipid Profile Among Young Adults in Sohag Governorate
- ClinicalTrials.gov ID
- NCT07062081
- Acronym / sponsor ID
- Soh-Med-25-06-18MS
- Conditions
- Acne Vulgaris
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 30 Jan 2026 (estimated)
- Study completion
- 30 Jan 2026 (estimated)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11
Detailed description
Acne vulgaris is a multifactorial disorder of the pilosebaceous unit, resulting from sebum overproduction, follicular hyperkeratinization, inflammation, and bacterial colonization of hair follicles by Propionibacterium acnes. The sebaceous gland is controlled primarily by hormonal stimulation. In this way, the hormonal effect on sebum secretion is a key to the pathogenesis of acne.12-16 During puberty, alteration of the sebum component, called dysseborrhea, stress, irritation, cosmetics, and potential dietary factors lead to the formation of acne lesions.16 Changes in sebum secretion are considered to be an important factor of acne. In this way, increased sebum secretion can induce acne occurrence.17 Increasing evidence, in essence, indicates that changes in lipid profile are strongly related to acne occurrence. Accordingly, further information and awareness campaigns are needed to emphasize the role of balanced lipid metabolism to control acne. Although a correlation between the incidence of acne and lipid profile levels has been observed before, it must be documented in each population with etiological characteristics. Minimal reports are available on the relationship between plasma lipids and acne in our country. Hence, we aim to establish this study to estimate the presence of lipid alteration in acne patients.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 12 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- age- and sex-matched healthy volunteers, not taking any medicine, and having no personal or family history of acne.
Key exclusion criteria (3 listed)
- : reluctance to take part in the study, pregnancy or lactation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| lipid profileThe blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values. | Diagnostic test | – |
Primary outcome
lipid profile (TG)
Time frame: 6 months
The blood samples were taken to measure lipid profile levels as triglycerides (TG)
lipid profile (HDL)
Time frame: 6 months
The blood samples were taken to measure lipid profile levels as HDL
lipid profile (VLDL)
Time frame: 6 months
The blood samples were taken to measure lipid profile levels as VLDL
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2025.
- Background: PubMed 18377339Degitz K, Ochsendorf F. Pharmacotherapy of acne. Expert Opin Pharmacother. 2008 Apr;9(6):955-71. doi: 10.1517/14656566.9.6.955.
- Background: PubMed 8876289Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996 Sep;35(9):633-9. doi: 10.1111/j.1365-4362.1996.tb03687.x.
- Background: PubMed 26059821Dreno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 5:14-9. doi: 10.1111/jdv.13188.
- Background: PubMed 17945383Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan;58(1):56-9. doi: 10.1016/j.jaad.2007.06.045. Epub 2007 Oct 22.
- Individual participant dataSharing planned: Undecided
Related trials for Acne Vulgaris
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
hanan A metwaly, professor contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing lipid profile in people with Acne Vulgaris, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hager A dardier, demonastrator (01129977680, hager.dardir@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
lipid profile (TG) (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07062081, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.